Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

• Status: Completed
• Trial end date: 2020-03-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Criteria

Key Inclusion Criteria:

• To have Lower Urinary Tract Symptoms for at least 12 weeks prior to study entry

• To have at least 1 urinary urgency episodes per day, and diurnal urinary frequency of 8 or more per day.

• To meet the detrusor underactivity criteria by urodynamic study

Key Exclusion Criteria:

• Neurogenic bladder by the central nervous system diseases.

• StageIII or more cystocele of pelvic organ prolapse quantification system (women)

• Prostate volume ≥30mL (Men)

• Any symptoms of Urinary tract infection (UTI)